GLUE Chief Medical Officer Filip Janku Buys $45K of Stock
Chief Medical Officer Filip Janku purchased 6,000 shares of Monte Rosa Therapeutics.
Reviewed by automated data checks against the source filing. How we make and check alerts
Filip Janku, Chief Medical Officer at Monte Rosa Therapeutics, Inc. ($GLUE), bought 6,000 shares at an average price of $7.56, worth about $45,360, on June 29, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $GLUE is down 2.7% after 1 week, down 9.8% after 1 month and down 59.2% to date (from the $23.90 close on Jun 29, 2026).
GLUE
Monte Rosa Therapeutics, Inc.
Key Points
- On June 29, 2026, Filip Janku, the Chief Medical Officer of Monte Rosa Therapeutics, bought 6,000 shares at $7.56 each, totaling $45,360.
- Monte Rosa Therapeutics, Inc. (NasdaqGS: GLUE) traded at $24.20 on Wednesday, with a market cap of approximately $2.04 billion and a 52-week high of $25.77.
- Analysts maintain a buy rating on Monte Rosa Therapeutics, with Guggenheim setting a price target of $35 as of June 30, 2026.
Get $GLUE trade alerts by text
We text you when insiders, Congress or big funds trade $GLUE. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Monte Rosa Therapeutics, Inc. alert may contain errors. Disclosures
Filip Janku, the Chief Medical Officer of Monte Rosa Therapeutics, Inc. (NasdaqGS: GLUE), recently increased his stake in the company. On June 29, 2026, Janku bought 6,000 shares at an average price of $7.56 each, bringing the total value of the transaction to $45,360. This purchase was not made under a pre-planned trading program.
Insider Buying and Selling at Monte Rosa Therapeutics, Inc.
On the same day, Janku also sold 6,000 shares at a price of $22.95, though this transaction was planned. Additionally, Anthony Manning, another insider, bought 10,000 shares at $4.16 and sold the same amount at $23.11, both on June 29, 2026.
Monte Rosa Therapeutics, Inc. Stock Up 99.5%
Shares of Monte Rosa Therapeutics traded around $24.20 on Wednesday. The company, which operates in the biotechnology sector, has a market capitalization of about $2.04 billion. It has a 52-week low of $4.12 and a high of $25.77. The stock's 50-day moving average is $19.09, while the 200-day moving average stands at $16.34. The company has a current ratio of 9.54, indicating strong liquidity, and a debt-to-equity ratio of 7.49.
Analysts Set New Price Targets
Analysts continue to show confidence in Monte Rosa Therapeutics. On June 30, 2026, Guggenheim maintained its buy rating, setting a price target of $35. Other firms like JP Morgan and Piper Sandler have also reiterated their buy ratings, with targets of $31 and $37, respectively. The consensus target price is around $32.33, based on six analyst opinions.
About Monte Rosa Therapeutics
Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Boston, Massachusetts. It focuses on developing small molecule precision medicines that use the body's natural processes to target and degrade specific proteins. The company is working on treatments for various conditions, including MYC-driven tumors and autoimmune diseases. Led by CEO Dr. Markus Warmuth, Monte Rosa employs 187 people and has collaborations with major firms like F. Hoffmann-La Roche Ltd. and Novartis.
Bottom Line
Insider buying can indicate confidence in a company's future, and Filip Janku's recent stock purchase adds to this narrative for Monte Rosa Therapeutics. The company's innovative approach to biotechnology, coupled with strong analyst support, makes it a stock to watch. Keep in mind, however, that 13F filings and insider trades may not reflect current positions.
Related Filing Alerts
Source: Filip Janku's Form 4 filing on $GLUE (Jun 29, 2026). Find the original filing: GLUE Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts